These findings showed that heparins and heparinoids can interact with PCSK9 via their negatively charged sulfated sugar groups and therefore bear the potential to be developed as PCSK9 inhibitors for the treatment of dyslipidemia (Gustafsen et al., 2017; Shrestha et al., 2021a; Shrestha et al., 2021b). The gene discussed is PCSK9; the disease is metabolic syndrome.